Literature DB >> 20945147

[New information on high risk breast screening].

C C Riedl1, L Ponhold, R Gruber, K Pinker, T H Helbich.   

Abstract

Women with an elevated risk for breast cancer require intensified screening beginning at an early age. Such high risk screening differs considerably from screening in the general population. After an expert has evaluated the exact risk a breast MRI examination should be offered at least once a year and beginning latest at the age of 30 depending on the patients risk category. Complementary mammograms should not be performed before the age of 35. An additional ultrasound examination is no longer recommended. To ensure a high sensitivity and specificity high risk screening should be performed only at a nationally or regionally approved and audited service. Adequate knowledge about the phenotypical characteristics of familial breast cancer is essential. Besides the common malignant phenotypes, benign morphologies (round or oval shape and smooth margins) as well as a low prevalence of calcifications have been described. Using MRI benign contrast media kinetics as well as non-solid lesions with focal, regional and segmental enhancement can often be visualized.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20945147     DOI: 10.1007/s00117-010-2011-z

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  29 in total

1.  Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer.

Authors:  Christiane K Kuhl; Simone Schrading; Claudia C Leutner; Nuschin Morakkabati-Spitz; Eva Wardelmann; Rolf Fimmers; Walther Kuhn; Hans H Schild
Journal:  J Clin Oncol       Date:  2005-11-20       Impact factor: 44.544

2.  Screening women at high risk for breast cancer with mammography and magnetic resonance imaging.

Authors:  Constance D Lehman; Jeffrey D Blume; Paul Weatherall; David Thickman; Nola Hylton; Ellen Warner; Etta Pisano; Stuart J Schnitt; Constantine Gatsonis; Mitchell Schnall; Gia A DeAngelis; Paul Stomper; Eric L Rosen; Michael O'Loughlin; Steven Harms; David A Bluemke
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

3.  Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).

Authors:  M O Leach; C R M Boggis; A K Dixon; D F Easton; R A Eeles; D G R Evans; F J Gilbert; I Griebsch; R J C Hoff; P Kessar; S R Lakhani; S M Moss; A Nerurkar; A R Padhani; L J Pointon; D Thompson; R M L Warren
Journal:  Lancet       Date:  2005 May 21-27       Impact factor: 79.321

4.  The significance of circumscribed malignant mammographic masses in the surveillance of BRCA 1/2 gene mutation carriers.

Authors:  R Kaas; R Kroger; J H C L Hendriks; A P E Besnard; W Koops; F A Pameijer; W Prevoo; C E Loo; S H Muller
Journal:  Eur Radiol       Date:  2004-04-09       Impact factor: 5.315

5.  Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force.

Authors:  Linda L Humphrey; Mark Helfand; Benjamin K S Chan; Steven H Woolf
Journal:  Ann Intern Med       Date:  2002-09-03       Impact factor: 25.391

6.  Multimodality screening of high-risk women: a prospective cohort study.

Authors:  Susan P Weinstein; A Russell Localio; Emily F Conant; Mark Rosen; Kathleen M Thomas; Mitchell D Schnall
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

7.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.

Authors:  Mieke Kriege; Cecile T M Brekelmans; Carla Boetes; Peter E Besnard; Harmine M Zonderland; Inge Marie Obdeijn; Radu A Manoliu; Theo Kok; Hans Peterse; Madeleine M A Tilanus-Linthorst; Sara H Muller; Sybren Meijer; Jan C Oosterwijk; Louk V A M Beex; Rob A E M Tollenaar; Harry J de Koning; Emiel J T Rutgers; Jan G M Klijn
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

8.  Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer.

Authors:  Christopher C Riedl; Lothar Ponhold; Daniel Flöry; Michael Weber; Regina Kroiss; Teresa Wagner; Michael Fuchsjäger; Thomas H Helbich
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531

9.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.

Authors:  Ellen Warner; Donald B Plewes; Kimberley A Hill; Petrina A Causer; Judit T Zubovits; Roberta A Jong; Margaret R Cutrara; Gerrit DeBoer; Martin J Yaffe; Sandra J Messner; Wendy S Meschino; Cameron A Piron; Steven A Narod
Journal:  JAMA       Date:  2004-09-15       Impact factor: 56.272

10.  Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI.

Authors:  J Veltman; R Mann; T Kok; I M Obdeijn; N Hoogerbrugge; J G Blickman; C Boetes
Journal:  Eur Radiol       Date:  2008-02-13       Impact factor: 5.315

View more
  2 in total

Review 1.  [Diagnostic imaging of breast cancer : An update].

Authors:  M Funke
Journal:  Radiologe       Date:  2016-10       Impact factor: 0.635

Review 2.  [The medical management of high risk individuals. Experiences with persons exposed to chronic internal irradiation].

Authors:  G van Kaick; S Delorme
Journal:  Radiologe       Date:  2011-12       Impact factor: 0.635

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.